| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $2.42 | - | - |
| Q3'26 | $2.82 | $3.17 | +12.5% |
| Q3'25 | $2.17 | $2.55 | +17.6% |
| Q2'25 | $2.03 | $2.08 | +2.4% |
| Q1'25 | $2.15 | $2.35 | +9.4% |
| Q4'24 | $1.76 | $1.93 | +9.4% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $65.9B | - | - |
| Q3'26 | $62.3B | $60.9B | -2.2% |
| Q3'25 | - | $64.0B | - |
| Q2'25 | - | $60.2B | - |
| Q1'25 | - | $54.9B | - |
| Q4'24 | - | $55.3B | - |
Market Data
CAH is currently trading at $235.80, giving Cardinal Health, Inc. a market cap of 55.17B and a P/E ratio of 35.5. Today's range spans $232.05–$236.26, with shares opening at $233.07 and moving up $0.18 (0.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 60/100.
Over the past year CAH has traded between $137.75 and $243.21 - the current price is +71.2% off the 52-week low and -3.0% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $249.60 (range $215.00–$275.00), implying upside of +5.9%.
Dividend-paying Healthcare stocks at the large-cap level tend to attract a different buyer mix than pure growth names - and CAH (55.17B market cap) with a BUY read (86/100) and bullish sentiment (60/100) benefits from both income-oriented and growth-oriented flows. The current P/E ratio stands at 35.5. Price: $235.80 (near 52-week highs in $137.75–$243.21). When technical momentum aligns with that dual-buyer base, the price path tends to be more durable than single-buyer-type momentum trades.
Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (60/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $235.80 (near 52-week highs), CAH's position within the $137.75–$243.21 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).